Cargando…

Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori

Helicobacter pylori is a Gram-negative bacterium responsible for the development of gastric diseases. The issue of spreading antibiotic resistance of H. pylori and its limited therapeutic options is an important topic in modern gastroenterology. This phenomenon is greatly associated with a very narr...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzyżek, Paweł, Paluch, Emil, Gościniak, Grażyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599531/
https://www.ncbi.nlm.nih.gov/pubmed/33007899
http://dx.doi.org/10.3390/antibiotics9100658
_version_ 1783602897734336512
author Krzyżek, Paweł
Paluch, Emil
Gościniak, Grażyna
author_facet Krzyżek, Paweł
Paluch, Emil
Gościniak, Grażyna
author_sort Krzyżek, Paweł
collection PubMed
description Helicobacter pylori is a Gram-negative bacterium responsible for the development of gastric diseases. The issue of spreading antibiotic resistance of H. pylori and its limited therapeutic options is an important topic in modern gastroenterology. This phenomenon is greatly associated with a very narrow range of antibiotics used in standard therapies and, as a consequence, an alarmingly high detection of multidrug-resistant H. pylori strains. For this reason, scientists are increasingly focused on the search for new substances that will not only exhibit antibacterial effect against H. pylori, but also potentiate the activity of antibiotics. The aim of the current review is to present scientific reports showing newly discovered or repurposed compounds with an ability to enhance the antimicrobial activity of classically used antibiotics against H. pylori. To gain a broader context in their future application in therapies of H. pylori infections, their antimicrobial properties, such as minimal inhibitory concentrations and minimal bactericidal concentrations, dose- and time-dependent mode of action, and, if characterized, anti-biofilm and/or in vivo activity are further described. The authors of this review hope that this article will encourage the scientific community to expand research on the important issue of synergistic therapies in the context of combating H. pylori infections.
format Online
Article
Text
id pubmed-7599531
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75995312020-11-01 Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori Krzyżek, Paweł Paluch, Emil Gościniak, Grażyna Antibiotics (Basel) Review Helicobacter pylori is a Gram-negative bacterium responsible for the development of gastric diseases. The issue of spreading antibiotic resistance of H. pylori and its limited therapeutic options is an important topic in modern gastroenterology. This phenomenon is greatly associated with a very narrow range of antibiotics used in standard therapies and, as a consequence, an alarmingly high detection of multidrug-resistant H. pylori strains. For this reason, scientists are increasingly focused on the search for new substances that will not only exhibit antibacterial effect against H. pylori, but also potentiate the activity of antibiotics. The aim of the current review is to present scientific reports showing newly discovered or repurposed compounds with an ability to enhance the antimicrobial activity of classically used antibiotics against H. pylori. To gain a broader context in their future application in therapies of H. pylori infections, their antimicrobial properties, such as minimal inhibitory concentrations and minimal bactericidal concentrations, dose- and time-dependent mode of action, and, if characterized, anti-biofilm and/or in vivo activity are further described. The authors of this review hope that this article will encourage the scientific community to expand research on the important issue of synergistic therapies in the context of combating H. pylori infections. MDPI 2020-09-30 /pmc/articles/PMC7599531/ /pubmed/33007899 http://dx.doi.org/10.3390/antibiotics9100658 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Krzyżek, Paweł
Paluch, Emil
Gościniak, Grażyna
Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori
title Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori
title_full Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori
title_fullStr Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori
title_full_unstemmed Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori
title_short Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori
title_sort synergistic therapies as a promising option for the treatment of antibiotic-resistant helicobacter pylori
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599531/
https://www.ncbi.nlm.nih.gov/pubmed/33007899
http://dx.doi.org/10.3390/antibiotics9100658
work_keys_str_mv AT krzyzekpaweł synergistictherapiesasapromisingoptionforthetreatmentofantibioticresistanthelicobacterpylori
AT paluchemil synergistictherapiesasapromisingoptionforthetreatmentofantibioticresistanthelicobacterpylori
AT gosciniakgrazyna synergistictherapiesasapromisingoptionforthetreatmentofantibioticresistanthelicobacterpylori